Factors that affect risk for hepatocellular carcinoma and effects of surveillance
- PMID: 21459158
- DOI: 10.1016/j.cgh.2011.03.027
Factors that affect risk for hepatocellular carcinoma and effects of surveillance
Abstract
Background & aims: The incidence of hepatocellular carcinoma (HCC) in the United States is increasing. Surveillance may affect the stage at diagnosis and consequently the treatment options available for HCC. We evaluated risk factors for HCC, the proportion of cases detected via surveillance, tumor characteristics, treatment approaches, and overall patient survival in a referral center cohort.
Methods: The study included all patients diagnosed with HCC at the Mayo Clinic, Rochester, Minnesota, from 2007 to 2009 (n = 460). Clinical information was retrospectively abstracted from the medical record.
Results: Hepatitis C virus (HCV, 36%), alcohol use (29%), and nonalcoholic fatty liver disease (NAFLD, 13%) were the most common risk factors for HCC. HCV was present in 56% of patients younger than 60. NAFLD was present in 19% of patients older than 60. HCC was detected during surveillance in 31% of patients. Patients with worse liver function were more likely to be on surveillance. Transarterial chemoembolization, surgical resection, and liver transplantation were the most common treatment approaches for HCC. Patients diagnosed with HCC during surveillance had less advanced disease, were more likely to be eligible for potentially curative treatments, and had increased survival times (P < .001).
Conclusions: At a major US referral center, the predominant HCC etiologies were HCV, alcohol use, and NAFLD. HCCs were detected during surveillance in the minority of patients. HCCs detected during surveillance were of less advanced stage, and patients were more likely to receive treatment that prolonged their survival.
Copyright © 2011 AGA Institute. Published by Elsevier Inc. All rights reserved.
Comment in
-
Metabolic syndrome and alcohol abuse: a potential hepatocarcinogenic mix in adolescents.Clin Gastroenterol Hepatol. 2012 Feb;10(2):204; author reply 204-5. doi: 10.1016/j.cgh.2011.07.013. Epub 2011 Jul 30. Clin Gastroenterol Hepatol. 2012. PMID: 21806950 No abstract available.
-
Hepatocellular carcinoma: still in search of evidence-based care.Clin Gastroenterol Hepatol. 2012 Feb;10(2):205; author reply 205-6. doi: 10.1016/j.cgh.2011.08.003. Epub 2011 Aug 11. Clin Gastroenterol Hepatol. 2012. PMID: 21839710 No abstract available.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical